PMN Stock Forecast & Price Target

ProMIS Neurosciences is attractive fundamentally because PMN310 appears to address the central commercial weakness of approved anti-amyloid therapies: meaningful efficacy has been constrained by ARIA risk, while its oligomer-selective design and zero ARIA-E in the 6-month blinded interim across all genotypes suggest a cleaner safety profile that could support broader dosing and retention. The trial has already enrolled 144 patients versus a 128-patient target, and the company ended 2Q26 with about $53.4MM in cash, which management says funds operations through 2027, reducing near-term financing pressure. With early biomarker improvements such as -15% pTau217 and -13.3% MTBR-tau243, plus a market opportunity in AD that could support multibillion-dollar annual sales if efficacy is confirmed, the shares offer substantial upside if the 1Q27 unblinded topline validates target engagement.

ProMIS Neurosciences is fundamentally a high-risk, pre-commercial biotechnology story whose lead asset PMN310 still faces major clinical validation risk, because the oligomer hypothesis has not been proven in humans and the Phase 1b interim biomarker results, while directionally supportive, do not establish functional efficacy. Although blinded data through Day 169 showed a 15% mean decline in plasma pTau217 versus a natural-history expectation of about a 6% increase over 18 months and a 13.3% decline in CSF MTBR-tau243, the company must still demonstrate that these signals translate into meaningful clinical benefit while avoiding unexpected safety issues such as ARIA. With 6.9 million U.S. patients over 65 affected by Alzheimer’s disease and a field crowded by approved, well-resourced anti-amyloid antibodies, the stock remains pressured by financing risk, competitive execution risk, and uncertainty that PMN310 can differentiate on both safety and efficacy.